|
|
|
|
| LEADER |
02841nam a22004815i 4500 |
| 001 |
978-3-662-44596-9 |
| 003 |
DE-He213 |
| 005 |
20151204191113.0 |
| 007 |
cr nn 008mamaa |
| 008 |
140906s2014 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783662445969
|9 978-3-662-44596-9
|
| 024 |
7 |
|
|a 10.1007/978-3-662-44596-9
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a QR355-502
|
| 072 |
|
7 |
|a MMFM
|2 bicssc
|
| 072 |
|
7 |
|a MED052000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.9101
|2 23
|
| 245 |
1 |
0 |
|a Microbicides for Prevention of HIV Infection
|h [electronic resource] /
|c edited by Jeremy Nuttall.
|
| 264 |
|
1 |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 2014.
|
| 300 |
|
|
|a IX, 179 p. 12 illus., 6 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Current Topics in Microbiology and Immunology,
|x 0070-217X ;
|v 383
|
| 505 |
0 |
|
|a Candidate Microbicides and Their Mechanisms of Action -- Microbicide Dosage Forms -- Preclinical Safety Evaluation -- Clinical Safety and Pharmacology Trial -- Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials -- Rectal Microbicide Development -- Developing Regulatory Strategy for Microbicides -- Preparing for Microbicide Introduction, Rollout and Sustained Access.
|
| 520 |
|
|
|a One of the most promising new approaches for the prevention of HIV transmission, particularly for developing countries, involves topical, self-administered products known as microbicides. The development of microbicides is a long and complicated process, and this volume provides an overview of all the critical areas, from the selection of appropriate candidate molecules and their formulation, preclinical and clinical testing for safety and efficacy, strategies for product registration and finally, issues associated with product launch, distribution and access. The book will prove valuable to both those working in the field and all others who are interested in learning more about this product class, which has the potential to significantly impact the future of this devastating epidemic.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Vaccines.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
|
0 |
|a Virology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Virology.
|
| 650 |
2 |
4 |
|a Vaccine.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 700 |
1 |
|
|a Nuttall, Jeremy.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783662445952
|
| 830 |
|
0 |
|a Current Topics in Microbiology and Immunology,
|x 0070-217X ;
|v 383
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-662-44596-9
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
